OralParenteralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Caffeine

CAS 58-08-2

Caffeine (CAS 58-08-2) is a Phase 4 pharmaceutical compound with 12 bioactivity targets and 3,536 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

3,536

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Caffeine

CAS Number

58-08-2

UNII

3G6A5W338E

InChIKey

RYYVLZVUVIJVGH-UHFFFAOYSA-N

ChEMBL ID

CHEMBL113

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

CafergotFioricetEsgicMigergotNorgesicVivarinCafcitOrphengesicPep-Back

dosed ingredientnatural productoralparenteraltherapeutic flagtopical

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL113 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 24 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Ki	36516.4673939394 nM	165	-
-	AC50	17810.003 nM	100	-
-	IC50	59307.786451612905 nM	31	-
-	Potency	16335.030000000002 nM	17	-
-	EC50	69900 nM	5	-
-	Kd	32263.771999999997 nM	5	-
-	MIC	400 ug.mL-1	1	-
Adenosine receptor A2a GPCR	Ki	5.61	-	Homo sapiens
Potassium voltage-gated channel subfamily H member 2 Ion channel	IC50	5.31	-	Homo sapiens
Adenosine receptor A1 GPCR	Ki	4.97	-	Homo sapiens
Adenosine receptor A2b GPCR	Ki	4.77	-	Homo sapiens
Adenosine receptor A3 GPCR	Ki	4.33	-	Homo sapiens
Acetylcholinesterase Enzyme	IC50	5.14	-	Homo sapiens
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase	IC50	4.12	-	Homo sapiens
Glycogen phosphorylase, muscle form Enzyme	IC50	4.13	-	Oryctolagus cuniculus
Adenosine receptor A1 GPCR	Ki	4.77	-	Rattus norvegicus
Adenosine receptor A2a GPCR	Ki	5.03	-	Rattus norvegicus
Adenosine receptor A1 GPCR	Ki	4.54	-	Bos taurus
Adenosine receptor A1 GPCR	Ki	4	-	Cavia porcellus
Adenosine A2 receptor GPCR	Ki	4.57	-	Rattus norvegicus
Adenosine receptor GPCR	Ki	4.22	-	Rattus norvegicus
Guanine deaminase Enzyme	Ki	4.99	-	Homo sapiens
Adenosine A2a receptor GPCR	Ki	4.1	-	Cavia porcellus
Adenosine receptor A2b GPCR	Ki	4.89	-	Mus musculus

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Completed suicide	6123	4307.798	10010144
Toxicity to various agents	7667	3023.842	10070863
Infusion related reaction	4922	1582.109	10051792
Overdose	3397	1169.042	10033295
Blood pressure fluctuation	1966	1062.019	10005746
Acute hepatic failure	1169	1060.435	10000804
Sinusitis	3360	746.795	10040753
Exposure to toxic agent	486	663.784	10053487
Rheumatoid arthritis	3571	659.018	10039073
Product dose omission issue	699	595.298	10084406
Muscle injury	1291	560.171	10028314
Lower respiratory tract infection	2221	540.368	10024968
Folliculitis	1366	537.538	10016936
Intentional product misuse	1592	526.349	10074903
Heart rate decreased	1457	517.883	10019301
Irritable bowel syndrome	1457	515.37	10023003
Nasopharyngitis	3442	447.597	10028810
Blister	1945	416.195	10005191
Blood pressure increased	2889	406.201	10005750
Metabolic acidosis	1282	403.168	10027417
Intentional overdose	1580	397.238	10022523
Duodenal ulcer perforation	1374	393.28	10013849
Helicobacter infection	1422	379.217	10054263
Oxygen saturation decreased	1883	378.953	10033318
Joint swelling	3833	378.594	10023232
Blood pressure diastolic abnormal	688	376.742	10005736
Ill-defined disorder	1430	369.487	10061520
Anti-cyclic citrullinated peptide antibody positive	1620	368.404	10068798
Sleep disorder due to general medical condition, insomnia type	959	361.526	10040986
Impaired healing	1563	358.478	10021519
Blood pressure systolic increased	1221	322.548	10005760
Hepatic enzyme increased	2575	321.248	10060795
Intentional product use issue	2363	316.456	10076308
Weight increased	3471	315.295	10047899
Pericarditis	1763	306.989	10034484
Injection site pain	309	299.541	10022086
Diarrhoea	4667	288.476	10012735
Hepatotoxicity	931	285.397	10019851
Anion gap	166	279.978	10002522
Disease progression	664	268.288	10061818
Body temperature increased	828	262.281	10005911
Blood pressure systolic abnormal	536	247.152	10005757
Drug ineffective	7117	239.34	10013709
Blood pressure diastolic decreased	641	234.328	10005737
Hepatic necrosis	290	233.826	10019692
Therapeutic product effect decreased	2292	225.353	10082201
Coagulopathy	629	225.03	10009802
Drug resistance	31	224.823	10059866
Respiratory arrest	808	218.383	10038669
Anaemia	2040	213.181	10002034

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 13 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
A 1 receptor ADORA1	Antagonist	4.349999904632568 pKi	8469419\|14563788
A 2A receptor ADORA2A	Antagonist	4.599999904632568 pKi	9920286\|14563788
A 2B receptor ADORA2B	Antagonist	4.46999979019165 pKi	19569717\|12014951\|18404493
A 3 receptor ADORA3	Antagonist	4.880000114440918 pKi	-
A 1 receptor Adora1	Antagonist	4.36 pKi	8182711\|1658821
A 2A receptor Adora2a	Antagonist	4.32 pKi	1658821\|10838015
A 2B receptor Adora2b	Antagonist	4.89 pKi	8135856
A 2B receptor Adora2b	Antagonist	4.52 pKi	8135856
A 3 receptor Adora3	Antagonist	4.0 pKi	19569717
IP 3 R1 ITPR1	Antagonist	-	-
RyR1 RYR1	Activator	-	-
RyR2 RYR2	Activator	-	-
RyR3 RYR3	Activator	-	-

SOURCE PharmGKB 60 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

CYP1A1 (PA27092) rs2472297

Allele T is associated with increased metabolism of caffeine as compared to allele C.

Evidence: -; PMID 27702941

CACNA1S (PA85) rs1800559

Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.

Evidence: -; PMID 11260227

ADORA2A (PA24584) rs35060421

Genotype TT is associated with increased anxiety when exposed to caffeine in healthy individuals as compared to genotypes T/del + del/del.

Evidence: -; PMID 12825092

ADORA2A (PA24584) rs5751876

Genotype TT is not associated with anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.

Evidence: -; PMID 22012471

ADORA2A (PA24584) rs5751876

Genotype TT is associated with increased Anxiety Disorders when exposed to caffeine.

Evidence: -; PMID 20520601

ADORA2A (PA24584) rs5751876

Genotype TT is associated with decreased habitual consumption of caffeine as compared to genotypes CC + CT.

Evidence: -; PMID 17616786

CYP1A2 (PA27093) rs762551

Genotype AA is associated with increased likelihood of Neural Tube Defects when exposed to caffeine in children as compared to genotypes AC + CC.

Evidence: -; PMID 20641098

CYP1A2 (PA27093) rs762551

Genotype AA is not associated with risk of Breast Neoplasms when exposed to caffeine in people with BRCA1 mutations.

Evidence: -; PMID 17507615

ADORA2A (PA24584) rs3761422

Genotype TT is associated with increased Anxiety Disorders when exposed to caffeine as compared to genotypes CC + CT.

Evidence: -; PMID 20520601

ADORA2A (PA24584) rs2298383

Genotype CC is associated with increased Anxiety Disorders when exposed to caffeine as compared to genotypes CT + TT.

Evidence: -; PMID 20520601

ADORA2A (PA24584) rs5751876

Allele C is not associated with risk of Parkinson Disease when exposed to caffeine.

Evidence: -; PMID 18759349

CYP1A2 (PA27093) rs2069514

Genotypes AA + AG are associated with decreased metabolism of caffeine as compared to genotype GG.

Evidence: -; PMID 10101295

CYP1A2 (PA27093) rs762551

Genotype AA is associated with increased metabolism of caffeine in people with heavy coffee consumption as compared to genotypes AC + CC.

Evidence: -; PMID 20390257

CYP1A2 (PA27093) rs762551

Genotype AA is associated with increased metabolism of caffeine in people with Tobacco Use Disorder as compared to genotypes AC + CC.

Evidence: -; PMID 17370067

CYP1A1 (PA27092) rs2470893

Allele T is associated with habitual consumption of caffeine as compared to allele C.

Evidence: -; PMID 21490707

CYP1A2 (PA27093) rs762551

Genotype CC is associated with decreased risk of Parkinson Disease when exposed to caffeine in people with coffee consumption as compared to genotype AA.

Evidence: -; PMID 21281405

ADORA2A (PA24584) rs2298383

Genotype CC is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype TT.

Evidence: -; PMID 18305461

- rs4822492

Genotype CC is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype GG.

Evidence: -; PMID 18305461

ADORA2A (PA24584) rs5751876

Genotype CC is associated with increased likelihood of being sensitive to caffeine when exposed to caffeine as compared to genotype TT.

Evidence: -; PMID 17329997

CYP1A2 (PA27093) rs762551

Allele A is not associated with risk of Parkinson Disease when exposed to caffeine.

Evidence: -; PMID 18759349

ADORA2A (PA24584) rs5751876

Genotype TT is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype CC.

Evidence: -; PMID 18305461

CYP1A2 (PA27093) rs762551

Allele C is not associated with habitual consumption of caffeine as compared to allele A.

Evidence: -; PMID 17616786

CYP1A2 (PA27093) rs35694136

Allele T is not associated with risk of Parkinson Disease when exposed to caffeine.

Evidence: -; PMID 18759349

DRD2 (PA27478) rs1110976

Genotype GG is associated with decreased anxiety when exposed to caffeine in people with no disease.

Evidence: -; PMID 18305461

CYP1A2 (PA27093) rs762551

Genotype CC is not associated with increased risk of Urinary Bladder Neoplasms when exposed to caffeine as compared to genotype AA.

Evidence: -; PMID 18798002

- rs2198843

Genotype CC is not associated with increased risk of Urinary Bladder Neoplasms when exposed to caffeine as compared to genotypes CG + GG.

Evidence: -; PMID 18798002

CYP1A2 (PA27093) rs2472299

Genotype AA is not associated with increased risk of Urinary Bladder Neoplasms when exposed to caffeine as compared to genotypes AG + GG.

Evidence: -; PMID 18798002

CYP2E1 (PA129) rs2070676

Genotype CC is not associated with increased risk of Urinary Bladder Neoplasms when exposed to caffeine as compared to genotype CG.

Evidence: -; PMID 18798002

SPECC1L (PA164718673) rs5751862

Genotype AA is not associated with increased Anxiety Disorders when exposed to caffeine as compared to genotypes AG + GG.

Evidence: -; PMID 20520601

SPECC1L (PA164718673) rs5760405

Genotype TT is not associated with increased Anxiety Disorders when exposed to caffeine as compared to genotypes CC + CT.

Evidence: -; PMID 20520601

SOURCE NLM RxNorm 13 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Caffeine	1886	SU	MTHSPL
caffeine	1886	SU	MTHSPL
CAFFEINE	1886	SU	MTHSPL
caffeine	1886	IN	RXNORM
Cafergot	20027	BN	RXNORM
Fioricet	175184	BN	RXNORM
Esgic	216971	BN	RXNORM
Migergot	218377	BN	RXNORM
Norgesic	218776	BN	RXNORM
Vivarin	220917	BN	RXNORM
Cafcit	261469	BN	RXNORM
Orphengesic	261599	BN	RXNORM
Pep-Back	747238	BN	RXNORM

SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Accidental injury	caffeine	LLT	C0151736
Acidosis	caffeine	LLT	C0001122
Acidosis	caffeine	PT	C0001122
Agitation	caffeine	LLT	C0085631
Agitation	caffeine	PT	C0085631
Blood creatinine increased	caffeine	PT	C0235431
Blood sodium increased	caffeine	PT	C0595878
Brain hypoxia	caffeine	LLT	C1527348
Brain hypoxia	caffeine	PT	C1527348
Brain injury	caffeine	LLT	C0270611
Brain injury	caffeine	PT	C0270611
Ca++ increased	caffeine	LLT	C0553702
Cardiac disorder	caffeine	LLT	C0018799
Cardiac disorder	caffeine	PT	C0018799
Cerebral haemorrhage	caffeine	LLT	C2937358
Cerebral haemorrhage	caffeine	PT	C2937358
Convulsion	caffeine	LLT	C0036572
Convulsion	caffeine	PT	C0036572
Creatinine increased	caffeine	LLT	C0151578
Deafness	caffeine	LLT	C0011053
Deafness	caffeine	PT	C0011053
Dermatitis	caffeine	PT	C0011603
Disseminated intravascular coagulation	caffeine	LLT	C0012739
Disseminated intravascular coagulation	caffeine	PT	C0012739
Dry skin	caffeine	LLT	C0151908
Dry skin	caffeine	PT	C0151908
Dyspnoea	caffeine	LLT	C0013404
Dyspnoea	caffeine	PT	C0013404
Ear and labyrinth disorders	caffeine	-	C0851354
Failure to thrive	caffeine	LLT	C0015544
Failure to thrive	caffeine	PT	C0015544
Feeling jittery	caffeine	LLT	C0549209
Feeling jittery	caffeine	PT	C0549209
Gastritis	caffeine	LLT	C0017152
Gastritis	caffeine	PT	C0017152
Gastrointestinal disorder	caffeine	LLT	C0017178
Gastrointestinal disorder	caffeine	PT	C0017178
Gastrointestinal haemorrhage	caffeine	LLT	C0017181
Gastrointestinal haemorrhage	caffeine	PT	C0017181
Haemoglobin	caffeine	PT	C0518015
Haemoglobin decreased	caffeine	LLT	C0162119
Haemoglobin decreased	caffeine	PT	C0162119
Haemorrhage	caffeine	LLT	C0019080
Haemorrhage	caffeine	PT	C0019080
Hypercalcaemia	caffeine	PT	C0020437
Hyperglycaemia	caffeine	LLT	C0020456
Hyperglycaemia	caffeine	PT	C0020456
Hypersensitivity	caffeine	LLT	C0020517
Hypersensitivity	caffeine	PT	C0020517
Hypertension	caffeine	LLT	C0020538
Hypertension	caffeine	PT	C0020538
Hypoglycaemia	caffeine	LLT	C0020615
Hypoglycaemia	caffeine	PT	C0020615
Immune system disorder	caffeine	LLT	C0021053
Immune system disorder	caffeine	PT	C0021053
Impaired healing	caffeine	LLT	C0151692
Impaired healing	caffeine	PT	C0151692
Infection	caffeine	LLT	C0009450
Infection	caffeine	PT	C0009450
Infestation	caffeine	PT	C1384353
Infestation NOS	caffeine	LLT	C0851341
Infusion site inflammation	caffeine	LLT	C1112470
Infusion site inflammation	caffeine	PT	C1112470
Infusion site phlebitis	caffeine	LLT	C1096460
Infusion site phlebitis	caffeine	PT	C1096460
Injury	caffeine	PT	C3263723
Irritability	caffeine	LLT	C0022107
Irritability	caffeine	PT	C0022107
Malnutrition	caffeine	LLT	C0162429
Malnutrition	caffeine	PT	C0162429
Necrotising colitis	caffeine	PT	C0948692
Necrotising enterocolitis neonatal	caffeine	PT	C1442826
Necrotizing enterocolitis	caffeine	LLT	C0520459
Nervous system disorder	caffeine	LLT	C0027765
Nervous system disorder	caffeine	PT	C0027765
Nervousness	caffeine	PT	C0027769
Pulmonary oedema	caffeine	LLT	C0034063
Pulmonary oedema	caffeine	PT	C0034063
Rash	caffeine	LLT	C0015230
Rash	caffeine	PT	C0015230

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Caffeine used for in pharmaceutical contexts?

Caffeine (CAS 58-08-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Caffeine?

Caffeine has 3,536 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Completed suicide, Toxicity to various agents, Infusion related reaction, Overdose, Blood pressure fluctuation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Caffeine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Caffeine with EU status "permitted".

What clinical phase is Caffeine in?

Caffeine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Caffeine?

Caffeine has 24 bioactivity rows in this page query. Rendered target entries include Adenosine receptor A2a, Potassium voltage-gated channel subfamily H member 2, Adenosine receptor A1, Adenosine receptor A2b, Adenosine receptor A3.